Core Viewpoint - Quoin Pharmaceuticals is launching a video series titled "Living with Netherton" to raise awareness about Netherton Syndrome, a rare genetic disease, coinciding with Rare Disease Day on February 28, 2025 [1][2][8] Company Initiatives - The "Living with Netherton" series is part of the broader NETHERTON NOW campaign aimed at increasing understanding and advocacy for Netherton Syndrome [2][5] - Future episodes will continue to highlight patient and family experiences, emphasizing the need for awareness and treatment options [4] Patient Experience - The first episode features Carmon McTigue, whose son faced a long and challenging journey to diagnosis, ultimately revealing the lack of approved treatments for Netherton Syndrome [3][5] - The story illustrates the severe impacts of the disease, including multiple hospitalizations and complications such as MRSA [3][6] Disease Overview - Netherton Syndrome is caused by mutations in the SPINK5 gene, leading to severe symptoms including excessive skin shedding and a high risk of complications [6][10] - Up to 20% of infants born with Netherton Syndrome do not survive, highlighting the urgent need for increased awareness and research [6] Product Development - Quoin's lead candidate, QRX003, is currently in four clinical trials, with recent data suggesting its potential efficacy as a treatment for Netherton Syndrome [7][10] - QRX003 is designed to improve skin barrier function and normalize skin shedding in patients [10] Community Engagement - The NETHERTON NOW website serves as a resource hub for patients and families, offering educational materials and updates on research advancements [9][12]

Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin's QRX003 product is on track to obtain the first regulatory approval for Netherton Syndrome. ASHBURN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the "NETHERTON N ...

Core Viewpoint - Quoin Pharmaceuticals Ltd. has launched the "NETHERTON NOW" campaign to raise awareness about Netherton Syndrome, a genetic disease with significant misdiagnosis rates and high mortality risk among infants [1][4]. Company Overview - Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [9]. - The company is developing therapeutic products, including QRX003, aimed at treating Netherton Syndrome and other rare conditions [9]. Netherton Syndrome Insights - Netherton Syndrome is characterized by severe skin issues, including excess skin shedding, red scaly skin, and a high risk of dehydration and infections [2][7]. - The condition is caused by a mutation in the SPINK5 gene, leading to significant physical, emotional, and social challenges for patients and their families [6][4]. Clinical Development - Quoin is conducting four ongoing clinical studies to evaluate the safety and efficacy of QRX003 in patients with Netherton Syndrome [3]. - Recent clinical data has shown promising results for QRX003, with photographic evidence demonstrating significant skin improvement after 12 weeks of treatment [3]. - A "whole body" clinical study has been approved by the U.S. Food and Drug Administration and will be led by Dr. Amy Paller at Northwestern University [3]. Campaign Objectives - The "NETHERTON NOW" campaign aims to increase public awareness, foster advocacy, and provide educational resources about Netherton Syndrome [4][5]. - The campaign also seeks to address the long diagnostic delays faced by patients and the lack of approved treatments [4]. Product Information - QRX003 is a topical lotion designed to improve skin barrier function and normalize skin shedding, addressing the core issues of Netherton Syndrome [8]. - The product utilizes proprietary delivery technology to act as a serine protease inhibitor, compensating for the absence of the LEKTI protein in affected patients [8].

Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a Competitive Broad Spectrum Serine Protease Inhibitor ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential e ...

Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body Surface Area to “Whole Body” ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from its ongoing Investigator Pedia ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) CEO Dr. Michael Myers, who shares the company's notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet medical needs for those with Netherton Syndrome (NS), a rare and sometimes fatal skin disease for which there is currently no approved ...

Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical Benefits from QRX003 Observed Across All Measured EndpointsBefore and After Dosing with QRX003 Photographs Available for Review On WebsiteNo Product Safety Concerns Identified in Any Quoin Netherton Study to Date ASHBURN, Va., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmace ...

ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), Series F warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 1 ...

Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface area over a 12-week periodStudy intended to generate data based on product use resembling potential real-world useThird Netherton Syndrome clinical study to be conducted under Quoin’s open Investigational New Drug application ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ...

ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. The announcement will provide an operational update regarding the Company’s achievements during the quarter and will detail financial highlights. About Quoin Pha ...